MOA Flashcards
low to moderate noncompetitive antagonist at NMDA receptors, persistent stimulation of NMDA receptors by glutamate is thought to possibly contribute to the symptomology of AD
NMDA Receptor Antagonist; Memantine (Namenda) MOA?
reversibly and non-competitively inhibits centrally active acetylcholinesterase, which results in increased levels of Ach available for synaptic transmission in the CNS
AD drugs Donepezil and Rivastigmine MOA?
may inhibit burst firing without affecting normal neuronal excitability
Levetiracetam MOA?
may block sodium channels or potentiate GABA
Topirimate MOA?
increases GABA availability, enhances action of GABA, mimics action at postsynaptic sites
Valproic acid MOA?
exact MOA is unk, but blocks voltage dependent sodium and chloride channels
Zonisamide MOA?
thought to affect voltage sensitive sodium channels and inhibit presynaptic release of glutamate and aspartate in the neuron
Lamotrigine MOA?
exact MOA is unclear, but thought to affect the NA+ channels, slowing influx of NA+ in the cortical neurons and slowing spread of abnormal activity
Carbamazepine (Tegretol) MOA?
inhibit and stabilize electrical discharges in the motor cortex of the brain by affecting the influx of sodium ions during generation of nerve impulses
Phenytoin (Dilantin) MOA?
binding the circulating TNF-alpha, rendering it inactive; reduces chemostatic affect of TNF alpha by reducing IL-6 and CRP, resulting in reduced infiltration of inflammatory cells into the joint; cell lysis also occurs
Biologic DMARDS (Non-TNF Biologics) Rituximab and Abatacept MOA?
folic acid antagonist, thought to affect leukocyte suppression, decreasing inflammation, decreasing inflammation that results from immunological byproducts
Disease modifying anti-rheumatic drugs (DMARDS) like Methotrexate?
inhibits conversion of arachidonic acid to prostaglandin, prostacyclin, and thromboxanes, all of which are mediators of pain and inflammation
NSAIDS MOA?
decreases inflammation by suppressing migration of polymorphonuclear leukocytes (neutrophils, eosinophils, and basophils) and reversing increased capillary permeability
Corticosteroids (Prednisone) MOA?
inhibits activation, degranulation and migration of neutrophils to area of gout attack, decreases inflammation and pain associated with gout attack; takes 18-24 to work and full effect is at 48 hours
Colchicine MOA?
increases excretion of serum uric acid by competitively inhibiting reabsorption of uric acid in kidney
Probenecid MOA?
decrease uric acid by selectively inhibiting xanthine oxidase, uric acid decreases, reducing risk of crystallization and gout attack
Antigouts (Allopurinol and Febuxostat) MOA?
inhibit bone reabsorption by reducing osteoclast number and fxn
Bisphosphonates MOA?
thickens cervical mucus to inhibit sperm mitigation, suppresses ovulation, lower mid-cycle peak of FSH and LH; slow egg movement through fallopian tube; thins endometrium
Progesterone MOA?